ALXO Stock Overview A clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
ALX Oncology Holdings Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for ALX Oncology Holdings Historical stock prices Current Share Price US$1.81 52 Week High US$17.83 52 Week Low US$1.19 Beta 0.98 1 Month Change 16.03% 3 Month Change 7.74% 1 Year Change -85.62% 3 Year Change -90.57% 5 Year Change n/a Change since IPO -93.97%
Recent News & Updates
Price target decreased by 18% to US$7.67 Dec 20
Alx Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer Dec 11
New major risk - Revenue and earnings growth Nov 14
ALX Oncology Holdings Inc. Appoints Alan Sandler as Chief Medical Officer Nov 14
ALX Oncology Holdings Inc. Announces Resignation of Sophia Randolph as Chief Medical Officer, Effective October 11, 2024 Oct 04
New minor risk - Market cap size Sep 26 See more updates
Price target decreased by 18% to US$7.67 Dec 20
Alx Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer Dec 11
New major risk - Revenue and earnings growth Nov 14
ALX Oncology Holdings Inc. Appoints Alan Sandler as Chief Medical Officer Nov 14
ALX Oncology Holdings Inc. Announces Resignation of Sophia Randolph as Chief Medical Officer, Effective October 11, 2024 Oct 04
New minor risk - Market cap size Sep 26
ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations Sep 12
ALX Oncology Holdings Inc. Announces First Patients Dosed with Evorpacept and Sarclisa as Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi Sep 04
Price target decreased by 30% to US$9.27 Aug 16
ALX Oncology Holdings Inc. Announces Board Changes Aug 07
Price target decreased by 7.9% to US$19.33 Aug 02
New major risk - Share price stability Aug 01
ALX Oncology Holdings Inc. Reports Topline Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients with HER2-Positive Gastric Cancer Aug 01
Founder notifies of intention to sell stock Jul 14
Founder recently sold US$63k worth of stock Jul 07
ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation Jun 27
Chief Financial Officer recently bought US$102k worth of stock Jun 18
Founder notifies of intention to sell stock Jun 08
ALX Oncology Holdings Inc. Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 Aspen-07 Clinical Trial in Patients with Advanced Bladder Cancer Jun 05
New major risk - Revenue and earnings growth May 12
Founder notifies of intention to sell stock May 08
ALX Oncology Appoints Allison Dillon as Chief Business Officer May 08
ALX Oncology Holdings Inc. Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer Apr 30
Less than half of directors are independent Apr 30
ALX Oncology Holdings Inc., Annual General Meeting, Jun 12, 2024 Apr 23
Founder notifies of intention to sell stock Apr 18
ALX Oncology: Trying To Justify The Hype Apr 18
ALX Oncology Holdings Inc. Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”) Apr 10
Founder notifies of intention to sell stock Apr 07
Is ALX Oncology Holdings (NASDAQ:ALXO) Using Debt In A Risky Way? Mar 12
Price target increased by 17% to US$20.07 Mar 08
Founder recently sold US$108k worth of stock Jan 07 ALX Oncology Holdings Inc. has completed a Follow-on Equity Offering in the amount of $54.998752 million. Oct 07
ALX Oncology Holdings Inc. has completed a Follow-on Equity Offering in the amount of $54.998752 million. Oct 06
New minor risk - Shareholder dilution Oct 06
ALX Oncology Holdings Inc. Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer Oct 05 ALX Oncology Holdings Inc. Appoints Jason Lettmann as Chief Executive Officer
New major risk - Revenue and earnings growth Aug 12
ALX Oncology Announces First Patient Dosed in ASPEN-07, a Phase 1 Study of Evorpacept for the Treatment of Patients with Urothelial Cancer Feb 17
Chief Medical Officer & Director exercised options to buy US$479k worth of stock. Dec 22
Alx Oncology Announces Initial Data from Aspen-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia Dec 14
Alx Oncology Announces Initial Data from Aspen-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia Dec 13
ALX Oncology Holdings Inc. Appoints Scott Garland to Its Board of Directors Nov 30
Price target decreased to US$35.00 Nov 16
High number of new and inexperienced directors Nov 16
Price target decreased to US$35.00 Nov 10
Price target decreased to US$38.88 Aug 15
ALX Oncology Holdings Inc. Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer Aug 12
Price target decreased to US$38.88 Aug 09
ALX Oncology GAAP EPS of -$0.81 misses by $0.18 Aug 08
ALX Oncology's Evorpacept Receives Fast Track Designation from FDA as First-Line Treatment for Head and Neck Squamous Cell Carcinoma Aug 02
ALX Oncology stock rises on FDA fast track status for evorpacept to treat head/neck cancer Aug 01
ALX Oncology stock rises 14% on evorpacept's FDA orphan drug status for blood cancer Jun 29
ALX Oncology Holdings Inc.(NasdaqGS:ALXO) dropped from Russell 2000 Growth Index Jun 26
Price target decreased to US$43.25 Jun 06
ALX Oncology Holdings Inc Announces Evorpacept Clinical Program Updates Jun 04
Price target decreased to US$45.63 May 19
Price target decreased to US$49.38 Apr 27
High number of new and inexperienced directors Apr 27
ALX Oncology Holdings Inc., Annual General Meeting, Jun 14, 2022 Apr 23
ALX Oncology Appoints Itziar Canamasas, Ph.D., to Its Board of Directors Apr 13
ALX Oncology Holdings Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Cancer Mar 04
ALX Oncology Holdings Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Cancer Mar 03
Price target decreased to US$54.75 Mar 01
ALX Oncology Is Turning Into An Also-Ran In Anti-CD47 Feb 15
Chief Financial Officer exercised options to buy US$225k worth of stock. Feb 12
Price target decreased to US$72.75 Dec 18
ALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Azacitidine, Demonstrating Safety and Preliminary Activity in Patients with Myelodysplastic Syndrome Dec 13
ALX Oncology Stock: Attractive After Recent Data And Slump In Price Nov 30
Chief Medical Officer & Director exercised options and sold US$487k worth of stock Nov 25
Price target decreased to US$89.50 Nov 10
Chief Medical Officer & Director notifies of intention to sell stock Oct 15
Alx Oncology Holdings Inc. Announces Initiation of Investigator-Sponsored Trial of Evorpacept (Alx148) in Patients with Indolent and Aggressive Non-Hodgkin Lymphoma Sep 19
Chief Medical Officer & Director notifies of intention to sell stock Sep 16
ALX Oncology Is The Next CD47 Biotech To Watch After Recent Acquisitions In This Space Sep 08
Independent Director Graham Walmsley has left the company Aug 28
Chief Financial Officer notifies of intention to sell stock Aug 21
Chief Medical Officer & Director notifies of intention to sell stock Aug 14
Here's Why We're Not Too Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Situation Jul 08
ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or Gastroesophageal Junction Cancer Jul 04 ALX Oncology Holdings Inc.(NasdaqGS:ALXO) dropped from Russell 2500 Value Index
ALX Oncology Announces Update on ASPEN-03 and ASPEN-04, the ALX148 Phase 2 Head and Neck Cancer Studies Jun 15
Chief Medical Officer & Director notifies of intention to sell stock Jun 14
ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with Keytruda (Pembrolizumab) for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma May 11
Dosing underway in ALX Oncology's ALX148 combo study in head and neck cancer May 10
VP of Finance & Chief Accounting Officer has left the company Apr 02
We're Not Very Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Rate Mar 25
President exercised options and sold US$1.1m worth of stock Mar 25
Full year 2020 earnings released Mar 20
ALX Oncology Announces Appointment of Sophia Randolph to Board of Directors Mar 16
New 90-day low: US$68.62 Mar 06
ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics Mar 05
Here's What ALX Oncology Holdings Inc.'s (NASDAQ:ALXO) Shareholder Ownership Structure Looks Like Feb 01
ALX Oncology: All Their Eggs In The Proverbial Basket Jan 07
Analysts update estimates Jan 07 Shareholder Returns ALXO US Biotechs US Market 7D 11.7% -1.9% -2.8% 1Y -85.6% -5.7% 24.1%
See full shareholder returns
Return vs Industry: ALXO underperformed the US Biotechs industry which returned -5.7% over the past year.
Return vs Market: ALXO underperformed the US Market which returned 24.1% over the past year.
Price Volatility Is ALXO's price volatile compared to industry and market? ALXO volatility ALXO Average Weekly Movement 15.5% Biotechs Industry Average Movement 10.9% Market Average Movement 6.3% 10% most volatile stocks in US Market 18.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: ALXO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ALXO's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer.
Show more ALX Oncology Holdings Inc. Fundamentals Summary How do ALX Oncology Holdings's earnings and revenue compare to its market cap? ALXO fundamental statistics Market cap US$82.28m Earnings (TTM ) -US$151.16m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ALXO income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$151.16m Earnings -US$151.16m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/03 23:54 End of Day Share Price 2025/01/03 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources ALX Oncology Holdings Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Alethia Young Cantor Fitzgerald & Co. Li Wang Watsek Cantor Fitzgerald & Co. Martin Auster Credit Suisse
Show 4 more analysts 
